BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27:215-223. [PMID: 22572889 DOI: 10.1097/yic.0b013e3283542457] [Cited by in Crossref: 244] [Cited by in F6Publishing: 68] [Article Influence: 27.1] [Reference Citation Analysis]
Number Citing Articles
1 Dhillon S. Duloxetine: a review of its use in the management of major depressive disorder in older adults. Drugs Aging 2013;30:59-79. [PMID: 23239363 DOI: 10.1007/s40266-012-0040-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
2 McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. Int J Neuropsychopharmacol 2016;19:pyw055. [PMID: 27312740 DOI: 10.1093/ijnp/pyw055] [Cited by in Crossref: 82] [Cited by in F6Publishing: 60] [Article Influence: 16.4] [Reference Citation Analysis]
3 Jiang LX, Huang GD, Su F, Wang H, Zhang C, Yu X. Vortioxetine administration attenuates cognitive and synaptic deficits in 5×FAD mice. Psychopharmacology (Berl) 2020;237:1233-43. [PMID: 31953648 DOI: 10.1007/s00213-020-05452-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Chokka P, Bougie J, Rampakakis E, Proulx J. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr 2019;24:338-47. [PMID: 29792585 DOI: 10.1017/S1092852918000913] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 4.7] [Reference Citation Analysis]
5 Mallery L, MacLeod T, Allen M, McLean-Veysey P, Rodney-Cail N, Bezanson E, Steeves B, LeBlanc C, Moorhouse P. Systematic review and meta-analysis of second-generation antidepressants for the treatment of older adults with depression: questionable benefit and considerations for frailty. BMC Geriatr 2019;19:306. [PMID: 31718566 DOI: 10.1186/s12877-019-1327-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
6 Rosenblat JD, Kakar R, McIntyre RS. The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Int J Neuropsychopharmacol 2015;19:pyv082. [PMID: 26209859 DOI: 10.1093/ijnp/pyv082] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 14.8] [Reference Citation Analysis]
7 Crocco EA, Jaramillo S, Cruz-Ortiz C, Camfield K. Pharmacological Management of Anxiety Disorders in the Elderly. Curr Treat Options Psychiatry 2017;4:33-46. [PMID: 28948135 DOI: 10.1007/s40501-017-0102-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
8 Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry 2014;14:276. [PMID: 25260373 DOI: 10.1186/s12888-014-0276-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
9 MacQueen GM, Frey BN, Ismail Z, Jaworska N, Steiner M, Lieshout RJ, Kennedy SH, Lam RW, Milev RV, Parikh SV, Ravindran AV; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. Can J Psychiatry 2016;61:588-603. [PMID: 27486149 DOI: 10.1177/0706743716659276] [Cited by in Crossref: 84] [Cited by in F6Publishing: 54] [Article Influence: 16.8] [Reference Citation Analysis]
10 McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17:1557-67. [PMID: 24787143 DOI: 10.1017/S1461145714000546] [Cited by in Crossref: 205] [Cited by in F6Publishing: 66] [Article Influence: 29.3] [Reference Citation Analysis]
11 Dale E, Pehrson AL, Jeyarajah T, Li Y, Leiser SC, Smagin G, Olsen CK, Sanchez C. Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function. CNS Spectr 2016;21:143-61. [PMID: 26346726 DOI: 10.1017/S1092852915000425] [Cited by in Crossref: 65] [Cited by in F6Publishing: 25] [Article Influence: 10.8] [Reference Citation Analysis]
12 Wolff A, Joshi RK, Ekström J, Aframian D, Pedersen AM, Proctor G, Narayana N, Villa A, Sia YW, Aliko A, McGowan R, Kerr AR, Jensen SB, Vissink A, Dawes C. A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs R D 2017;17:1-28. [PMID: 27853957 DOI: 10.1007/s40268-016-0153-9] [Cited by in Crossref: 107] [Cited by in F6Publishing: 61] [Article Influence: 26.8] [Reference Citation Analysis]
13 Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012;10:CD006533. [PMID: 23076926 DOI: 10.1002/14651858.CD006533.pub2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
14 Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology 2015;40:2025-37. [PMID: 25687662 DOI: 10.1038/npp.2015.52] [Cited by in Crossref: 160] [Cited by in F6Publishing: 116] [Article Influence: 26.7] [Reference Citation Analysis]
15 Christensen MC, Florea I, Lindsten A, Baldwin DS. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol 2018;32:1086-97. [PMID: 30047820 DOI: 10.1177/0269881118788826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
16 Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29:138-149. [PMID: 24257717 DOI: 10.1097/yic.0000000000000018] [Cited by in Crossref: 102] [Cited by in F6Publishing: 28] [Article Influence: 14.6] [Reference Citation Analysis]
17 Sharp AM, Lertphinyowong S, Yee SS, Paredes D, Gelfond J, Johnson-Pais TL, Leach RJ, Liss M, Risinger AL, Sullivan AC, Thompson IM, Morilak DA. Vortioxetine reverses medial prefrontal cortex-mediated cognitive deficits in male rats induced by castration as a model of androgen deprivation therapy for prostate cancer. Psychopharmacology (Berl) 2019;236:3183-95. [PMID: 31139875 DOI: 10.1007/s00213-019-05274-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Carta MG, Pala AN, Finco G, Musu M, Moro MF. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clin Pract Epidemiol Ment Health 2015;11:144-9. [PMID: 25893002 DOI: 10.2174/1745017901511010144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Bortolato B, Miskowiak KW, Köhler CA, Maes M, Fernandes BS, Berk M, Carvalho AF. Cognitive remission: a novel objective for the treatment of major depression? BMC Med 2016;14:9. [PMID: 26801406 DOI: 10.1186/s12916-016-0560-3] [Cited by in Crossref: 104] [Cited by in F6Publishing: 68] [Article Influence: 20.8] [Reference Citation Analysis]
20 Behlke LM, Lenze EJ, Carney RM. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs 2020;34:1133-47. [PMID: 33064291 DOI: 10.1007/s40263-020-00763-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
21 Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014;29:470-82. [PMID: 25087600 DOI: 10.1002/hup.2424] [Cited by in Crossref: 69] [Cited by in F6Publishing: 44] [Article Influence: 11.5] [Reference Citation Analysis]
22 Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014;19:121-33. [PMID: 23903233 DOI: 10.1017/S1092852913000540] [Cited by in Crossref: 91] [Cited by in F6Publishing: 30] [Article Influence: 11.4] [Reference Citation Analysis]
23 Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev 2017;7:CD011520. [PMID: 28677828 DOI: 10.1002/14651858.CD011520.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
24 Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav 2017;7:e00622. [PMID: 28293465 DOI: 10.1002/brb3.622] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
25 Segura-Garcia C, Rania M, Carbone EA, de Filippis R, Aloi M, Caroleo M, Grasso G, Calabrò G, Fazia G, Staltari FA, Falvo A, Pugliese V, Gaetano R, Steardo L Jr, De Fazio P. Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression. Front Psychiatry 2021;12:635502. [PMID: 33815170 DOI: 10.3389/fpsyt.2021.635502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Lam RW, Kennedy SH, Mclntyre RS, Khullar A. Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. Can J Psychiatry 2014;59:649-54. [PMID: 25702365 DOI: 10.1177/070674371405901206] [Cited by in Crossref: 160] [Cited by in F6Publishing: 104] [Article Influence: 26.7] [Reference Citation Analysis]
27 Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat 2015;11:875-88. [PMID: 25848287 DOI: 10.2147/NDT.S73261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
28 Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM, McInerney SJ, McIntosh D, Milev RV, Müller DJ, Parikh SV, Pearson NL, Ravindran AV, Uher R; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 2016;61:540-60. [PMID: 27486148 DOI: 10.1177/0706743716659417] [Cited by in Crossref: 357] [Cited by in F6Publishing: 252] [Article Influence: 71.4] [Reference Citation Analysis]
29 Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014;28:855-74. [PMID: 25145538 DOI: 10.1007/s40263-014-0195-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
30 Alam MY, Jacobsen PL, Chen Y, Serenko M, Mahableshwarkar AR. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2014;29:36-44. [PMID: 24169027 DOI: 10.1097/yic.0000000000000010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 16] [Article Influence: 5.6] [Reference Citation Analysis]
31 El Mansari M, Lecours M, Blier P. Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacology (Berl) 2015;232:2343-52. [PMID: 25665528 DOI: 10.1007/s00213-015-3870-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
32 Gonda X, Pompili M, Serafini G, Carvalho AF, Rihmer Z, Dome P. The role of cognitive dysfunction in the symptoms and remission from depression. Ann Gen Psychiatry 2015;14:27. [PMID: 26396586 DOI: 10.1186/s12991-015-0068-9] [Cited by in Crossref: 82] [Cited by in F6Publishing: 56] [Article Influence: 13.7] [Reference Citation Analysis]
33 Zuckerman H, Pan Z, Park C, Brietzke E, Musial N, Shariq AS, Iacobucci M, Yim SJ, Lui LMW, Rong C, McIntyre RS. Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder. Front Psychiatry 2018;9:655. [PMID: 30564155 DOI: 10.3389/fpsyt.2018.00655] [Cited by in Crossref: 65] [Cited by in F6Publishing: 38] [Article Influence: 21.7] [Reference Citation Analysis]
34 Palazzo MC, Arici C, Cremaschi L, Cristoffanini M, Dobrea C, Dell'Osso B, Altamura AC. Cognitive Performance in Euthymic Patients with Bipolar Disorder vs Healthy Controls: A Neuropsychological Investigation. Clin Pract Epidemiol Ment Health 2017;13:71-81. [PMID: 28868081 DOI: 10.2174/1745017901713010071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
35 Pehrson AL, Pedersen CS, Tølbøl KS, Sanchez C. Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission. Front Pharmacol 2018;9:162. [PMID: 29559911 DOI: 10.3389/fphar.2018.00162] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
36 Waller JA, Nygaard SH, Li Y, du Jardin KG, Tamm JA, Abdourahman A, Elfving B, Pehrson AL, Sánchez C, Wernersson R. Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents. BMC Neurosci 2017;18:56. [PMID: 28778148 DOI: 10.1186/s12868-017-0376-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
37 Vieta E, Florea I, Schmidt SN, Areberg J, Ettrup A. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2019;34:153-60. [PMID: 31094901 DOI: 10.1097/YIC.0000000000000271] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
38 Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2014;10:1297-307. [PMID: 25075188 DOI: 10.2147/NDT.S41387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
39 Alboni S, Benatti C, Colliva C, Radighieri G, Blom JMC, Brunello N, Tascedda F. Vortioxetine Prevents Lipopolysaccharide-Induced Memory Impairment Without Inhibiting the Initial Inflammatory Cascade. Front Pharmacol 2020;11:603979. [PMID: 33613281 DOI: 10.3389/fphar.2020.603979] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Felice D, Guilloux JP, Pehrson A, Li Y, Mendez-David I, Gardier AM, Sanchez C, David DJ. Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism. Front Pharmacol 2018;9:204. [PMID: 29593535 DOI: 10.3389/fphar.2018.00204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
41 Leiser SC, Pehrson AL, Robichaud PJ, Sanchez C. Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. Br J Pharmacol 2014;171:4255-72. [PMID: 24846338 DOI: 10.1111/bph.12782] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
42 Matsuno K, Nakamura K, Aritomi Y, Nishimura A. Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults. Clin Pharmacol Drug Dev 2018;7:319-31. [PMID: 28941196 DOI: 10.1002/cpdd.381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
43 Jaeger J. Digit Symbol Substitution Test: The Case for Sensitivity Over Specificity in Neuropsychological Testing. J Clin Psychopharmacol 2018;38:513-9. [PMID: 30124583 DOI: 10.1097/JCP.0000000000000941] [Cited by in Crossref: 107] [Cited by in F6Publishing: 45] [Article Influence: 35.7] [Reference Citation Analysis]
44 Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13:217-231. [PMID: 28257128 DOI: 10.1038/nrneurol.2017.27] [Cited by in Crossref: 382] [Cited by in F6Publishing: 278] [Article Influence: 95.5] [Reference Citation Analysis]
45 Holper L. Conditional power of antidepressant network meta-analysis. BMC Psychiatry 2021;21:129. [PMID: 33673822 DOI: 10.1186/s12888-021-03094-5] [Reference Citation Analysis]
46 Smith J, Browning M, Conen S, Smallman R, Buchbjerg J, Larsen KG, Olsen CK, Christensen SR, Dawson GR, Deakin JF, Hawkins P, Morris R, Goodwin G, Harmer CJ. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Mol Psychiatry 2018;23:1127-33. [PMID: 28533517 DOI: 10.1038/mp.2017.104] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
47 Lowe P, Krivoy A, Porffy L, Henriksdottir E, Eromona W, Shergill SS. When the drugs don't work: treatment-resistant schizophrenia, serotonin and serendipity. Ther Adv Psychopharmacol 2018;8:63-70. [PMID: 29344345 DOI: 10.1177/2045125317737003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
48 Harrison JE, Lophaven S, Olsen CK. Which Cognitive Domains are Improved by Treatment with Vortioxetine? Int J Neuropsychopharmacol 2016;19:pyw054. [PMID: 27231256 DOI: 10.1093/ijnp/pyw054] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
49 Meeker AS, Herink MC, Haxby DG, Hartung DM. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Syst Rev 2015;4:21. [PMID: 25874839 DOI: 10.1186/s13643-015-0001-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
50 Martis LS, Højgaard K, Holmes MC, Elfving B, Wiborg O. Vortioxetine ameliorates anhedonic-like behaviour and promotes strategic cognitive performance in a rodent touchscreen task. Sci Rep 2021;11:9113. [PMID: 33907240 DOI: 10.1038/s41598-021-88462-7] [Reference Citation Analysis]
51 Bennabi D, Haffen E, Van Waes V. Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research. Front Psychiatry 2019;10:771. [PMID: 31780961 DOI: 10.3389/fpsyt.2019.00771] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
52 Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, Van Noord M, Lux L, Gaynes BN. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf 2014;37:19-31. [PMID: 24338044 DOI: 10.1007/s40264-013-0129-4] [Cited by in Crossref: 71] [Cited by in F6Publishing: 39] [Article Influence: 10.1] [Reference Citation Analysis]
53 Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat 2019;15:1249-58. [PMID: 31190831 DOI: 10.2147/NDT.S199746] [Cited by in Crossref: 42] [Cited by in F6Publishing: 10] [Article Influence: 21.0] [Reference Citation Analysis]
54 Mills NT, Sampson E, Fourrier C, Baune BT. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial. Int J Neuropsychopharmacol 2021;24:314-21. [PMID: 33269395 DOI: 10.1093/ijnp/pyaa092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Beyer JL, Johnson KG. Advances in Pharmacotherapy of Late-Life Depression. Curr Psychiatry Rep 2018;20:34. [PMID: 29627920 DOI: 10.1007/s11920-018-0899-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
56 Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci 2015;40:174-86. [PMID: 25350320 DOI: 10.1503/jpn.140120] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
57 Dale E, Zhang H, Leiser SC, Xiao Y, Lu D, Yang CR, Plath N, Sanchez C. Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. J Psychopharmacol 2014;28:891-902. [PMID: 25122043 DOI: 10.1177/0269881114543719] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
58 McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat 2017;13:2913-9. [PMID: 29238196 DOI: 10.2147/NDT.S150589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
59 Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016;30:242-52. [PMID: 26864543 DOI: 10.1177/0269881116628440] [Cited by in Crossref: 63] [Cited by in F6Publishing: 39] [Article Influence: 12.6] [Reference Citation Analysis]
60 Bobo W, Kelliny M, Croarkin P, Moore K. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. TCRM. [DOI: 10.2147/tcrm.s55313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
61 Morimoto SS, Kanellopoulos D, Manning KJ, Alexopoulos GS. Diagnosis and treatment of depression and cognitive impairment in late life. Ann N Y Acad Sci 2015;1345:36-46. [PMID: 25655026 DOI: 10.1111/nyas.12669] [Cited by in Crossref: 61] [Cited by in F6Publishing: 33] [Article Influence: 10.2] [Reference Citation Analysis]
62 Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015;232:2061-70. [PMID: 25575488 DOI: 10.1007/s00213-014-3839-0] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
63 Wallace A, Pehrson AL, Sánchez C, Morilak DA. Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. Int J Neuropsychopharmacol 2014;17:1695-706. [PMID: 24852131 DOI: 10.1017/S1461145714000571] [Cited by in Crossref: 72] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
64 Ostuzzi G, Gastaldon C, Barbato A, D'Avanzo B, Tettamanti M, Monti I, Aguglia A, Aguglia E, Alessi MC, Amore M, Bartoli F, Biondi M, Bortolaso P, Callegari C, Carrà G, Caruso R, Cavallotti S, Crocamo C, D'Agostino A, De Fazio P, Di Natale C, Giusti L, Grassi L, Martinotti G, Nosé M, Papola D, Purgato M, Rodolico A, Roncone R, Tarsitani L, Turrini G, Zanini E, Amaddeo F, Ruggeri M, Barbui C. Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial. Trials 2020;21:695. [PMID: 32746941 DOI: 10.1186/s13063-020-04460-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Burke AD, Goldfarb D, Bollam P, Khokher S. Diagnosing and Treating Depression in Patients with Alzheimer's Disease. Neurol Ther 2019;8:325-50. [PMID: 31435870 DOI: 10.1007/s40120-019-00148-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
66 Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat 2014;10:349-54. [PMID: 24570588 DOI: 10.2147/NDT.S39544] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
67 Chakrabarty T, Hadjipavlou G, Lam RW. Cognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management. Focus (Am Psychiatr Publ) 2016;14:194-206. [PMID: 31975803 DOI: 10.1176/appi.focus.20150043] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
68 Baune BT, Brignone M, Larsen KG. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder. Int J Neuropsychopharmacol 2018;21:97-107. [PMID: 29053849 DOI: 10.1093/ijnp/pyx070] [Cited by in Crossref: 47] [Cited by in F6Publishing: 24] [Article Influence: 23.5] [Reference Citation Analysis]